Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.74 |
| ▸ | RAF1 | P04049 | 5/20 | 0.67 |
| ▸ | EGFR | P00533 | 8/20 | 0.64 |
| ▸ | KDR | P35968 | 7/20 | 0.64 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239835 | 0.92 | BRAF (0.64) | BRAFRAF1EGFRKDRFLT3 | |
| SCHEMBL13234663 | 0.85 | BRAF (1.00) | BRAFRAF1EGFRKDRFLT3 | |
| SCHEMBL1013264 | 0.80 | BRAF (1.00) | BRAFRAF1EGFRKDRFLT3 | |
| SCHEMBL1013427 | 0.79 | BRAF (0.77) | BRAFRAF1 | |
| SCHEMBL13234456 | 0.77 | RAF1 (0.69) | BRAFRAF1FLT3MAPK14 | |
| SCHEMBL13234895 | 0.76 | NTRK1 (0.54) | BRAFRAF1KDRFLT3MAPK14 | |
| SCHEMBL13234371 | 0.76 | RAF1 (0.86) | BRAFRAF1FLT3MAPK14 | |
| SCHEMBL13200399 | 0.75 | BRAF (0.81) | BRAFRAF1EGFRKDRFLT3 | |
| SCHEMBL13234432 | 0.74 | RAF1 (0.93) | RAF1FLT3MAPK14 | |
| SCHEMBL1780247 | 0.74 | BRAF (1.00) | BRAFRAF1EGFRKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1684762-A4 | UREA DERIVATIVES AS KINASE MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1684762-A2 | UREA DERIVATIVES AS KINASE MODULATORS | Ambit Biosciences Corporation (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050267182-A1 | Urea derivatives as FLT-3 modulators | AMBIT BIOSCIENCES CORPORATION | 2005-12-01 | — | — | US | disclosed |
| US-20050197371-A1 | Urea derivatives as PDGFR modulators | AMBIT BIOSCIENCES CORPORATION | 2005-09-08 | — | — | US | disclosed |
| US-20050192314-A1 | Urea derivatives as C-kit modulators | AMBIT BIOSCIENCES CORPORATION | 2005-09-01 | — | — | US | disclosed |
| US-20050165024-A1 | Urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION | 2005-07-28 | — | — | US | disclosed |
| US-20050165031-A1 | Urea derivatives as ABL modulators | AMBIT BIOSCIENCES CORPORATION | 2005-07-28 | — | — | US | disclosed |
| WO-2005048948-A2 | UREA DERIVATIVES AS KINASE MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165024-A1 | Urea derivatives as kinase modulators | ULK2, ULK1, ULK3 | BRAF 139/4885RAF1 115/4885EGFR 971/4885 |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | BRAF 191/4885RAF1 372/4885EGFR 196/4885 |
| US-20050192314-A1 | Urea derivatives as C-kit modulators | KIT, PRKCH, PRKCE | BRAF 109/4885RAF1 135/4885EGFR 942/4885 |
| US-20050267182-A1 | Urea derivatives as FLT-3 modulators | FLT4, FLT1, FLT3 | BRAF 319/4885RAF1 338/4885EGFR 215/4885 |
| US-20050197371-A1 | Urea derivatives as PDGFR modulators | PDGFRA, PDGFRB, PDGFA | BRAF 537/4885RAF1 636/4885EGFR 17/4885 |
| US-20050165031-A1 | Urea derivatives as ABL modulators | ABL1, ABL2, BCR | BRAF 191/4885RAF1 372/4885EGFR 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.